Castleberry Anthony W, DeVore Adam D, Southerland Kevin W, Meza James M, Irish William D, Rogers Joseph G, Milano Carmelo A, Patel Chetan B
From the *Department of Surgery, Duke University Medical Center, Durham, North Carolina; †Division of Cardiovascular and Thoracic Surgery, Duke University Medical Center, Durham, North Carolina; ‡Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina; and §CTI, Clinical Trial and Consulting Services, Raleigh, North Carolina.
ASAIO J. 2016 May-Jun;62(3):232-9. doi: 10.1097/MAT.0000000000000329.
The proportion of heart transplant recipients bridged with durable, intracorporeal left ventricular assist devices (dLVADs) has dramatically increased; however, concern exists regarding obligate repeat sternotomy, increased bleeding risk because of anticoagulation and acquired von Willebrand disease, and increased rates of allosensitization. Whether dLVAD patients have impaired posttransplant outcomes compared with equivalent patients with less invasive intraaortic balloon pump counterpulsation (IABP) at the time of transplant is unknown. Therefore, we analyzed adult, first time, heart-only transplant procedures with dLVAD (n = 2,636) compared with IABP (n = 571) at the time of transplant based on data from the United Network for Organ Sharing (UNOS) July 2004 to December 2011. There was clear geographic variation in IABP and dLVAD at transplant. Multivariable analysis demonstrated equivalent cumulative risk of death (adjusted Cox proportional hazard ratio, 1.08; 95% confidence interval, 0.87-1.33; p = 0.51). There was no significant difference in adjusted comparison of perioperative morality, length of stay, postoperative renal failure requiring dialysis, or early acute rejection (p ≥ 0.14 for all). Therefore, data from UNOS suggest that the presence of dLVAD at the time of heart transplantation does not have a detrimental effect on postoperative outcomes compared with IABP, which must be considered in the context of pretransplant mortality and locoregional organ availability.
接受耐用型体内左心室辅助装置(dLVAD)过渡的心脏移植受者比例显著增加;然而,对于必须进行再次胸骨切开术、抗凝及获得性血管性血友病导致的出血风险增加以及同种致敏率升高存在担忧。与移植时采用侵入性较小的主动脉内球囊反搏(IABP)的同等患者相比,dLVAD患者移植后的结局是否受损尚不清楚。因此,我们根据器官共享联合网络(UNOS)2004年7月至2011年12月的数据,分析了成人首次单纯心脏移植手术,比较了移植时使用dLVAD的患者(n = 2636)和使用IABP的患者(n = 571)。移植时IABP和dLVAD的使用存在明显的地域差异。多变量分析显示死亡累积风险相当(校正后的Cox比例风险比为1.08;95%置信区间为0.87 - 1.33;p = 0.51)。围手术期死亡率、住院时间、术后需要透析的肾衰竭或早期急性排斥反应的校正比较均无显著差异(所有p≥0.14)。因此,UNOS的数据表明,与IABP相比,心脏移植时存在dLVAD对术后结局没有不利影响,这一点必须结合移植前死亡率和局部器官可用性来考虑。